|
|
Volumn 15, Issue 3, 2008, Pages 299-300
|
|
Assessment of new technologies: Surrogate endpoints versus outcomes, and the cost of health care
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CALCIUM;
EZETIMIBE;
EZETIMIBE PLUS SIMVASTATIN;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PLACEBO;
SIMVASTATIN;
TORCETRAPIB;
ARTERY INTIMA PROLIFERATION;
ATHEROSCLEROSIS;
BIOMEDICAL TECHNOLOGY ASSESSMENT;
BIOTECHNOLOGY;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
DRUG COST;
DRUG MEGADOSE;
DRUG SAFETY;
EDITORIAL;
EVIDENCE BASED MEDICINE;
FAMILIAL HYPERCHOLESTEROLEMIA;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE COST;
HEALTH CARE QUALITY;
HEALTH INSURANCE;
HUMAN;
IMAGING SYSTEM;
MONOTHERAPY;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
UNSPECIFIED SIDE EFFECT;
ADULT;
CORONARY ARTERY DISEASE;
FEMALE;
HEALTH CARE COSTS;
HUMANS;
IMAGE ENHANCEMENT;
MALE;
MIDDLE AGED;
OUTCOME ASSESSMENT (HEALTH CARE);
RADIOPHARMACEUTICALS;
REPRODUCIBILITY OF RESULTS;
SENSITIVITY AND SPECIFICITY;
SOFTWARE;
SOFTWARE VALIDATION;
TECHNETIUM TC 99M SESTAMIBI;
TECHNOLOGY ASSESSMENT, BIOMEDICAL;
TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;
VENTRICULAR DYSFUNCTION, LEFT;
|
|
EID: 44149085910
PISSN: 10713581
EISSN: None
Source Type: Journal
DOI: 10.1016/j.nuclcard.2008.04.004 Document Type: Editorial |
|
Times cited : (4)
|
|
References (8)
|
